Closed · RFA-NS-24-037 · CFDA 93.853;93.866 · Discretionary

Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $1M
Award range
Closed
Status
November 19, 2024
Close date
-
Expected awards

The verdict

Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $1,000,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $1M
award range
Closed
application status
93.853;93.866
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Optimization of Genome Editing Therapeutics f… is closed (last close November 19, 2024). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed November 19, 2024

Posted Aug 13 Closes Nov 19

Instrument

Cooperative Agreement

Description

This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This NOFO is not specific for any one or group within the ADRD spectrum of disorders. Disorders include; Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Multiples Etiology Dementias (MED).

Wide-open applicant board · 15 Grants.gov doors

Optimization of Genome Editing Therapeutics f… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Health (HL). This eligibility-code string dominates the National Institutes of Health book (9,741 peers, 78% of 12,420).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 05
Independent school districts
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH Grants Information grantsinfo@nih.gov

What to do next

Optimization of Genome Editing Therapeutics f… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.853;93.866 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants